



SINGAPORE, 24 JULY 2020

## HSA UPDATES

*“HSA UPDATES” addresses topics of current public interest and is subject to change as more information becomes available.*  
HSA UPDATES NO 9/2020

### RECALL OF TWO BATCHES (R14347H, R14347L) OF MINIRIN NASAL SPRAY DUE TO DETECTION OF HIGHER CONCENTRATION OF ACTIVE INGREDIENT

The Health Sciences Authority (HSA) is overseeing the recall of two batches of Minirin Nasal Spray 10mcg/dose marketed by Ferring Pharmaceuticals Pte Ltd. Some of the products in these two batches have been detected to contain a higher concentration of the active ingredient, desmopressin. The other batches of this product are not affected by this recall. Please refer to Table A for the affected batch numbers and **Annex A** for pictures of the medicine.

**Table A: Recalled batches of Minirin Nasal Spray**

Batch Number	Expiry
R14347H	July 2022
R14347L	July 2022

2 Minirin Nasal Spray is a prescription-only medicine used to control the production of urine in patients with central diabetes insipidus (CDI), a rare condition characterised by constant thirst and excessive urination, and also used as a diagnostic aid to examine kidney function.

3 The risk of experiencing serious side effects with the use of the affected batches is low in most patients as patients are generally trained to monitor and adjust their dose according to the symptoms they experience. In situations where the

patients are not able to adjust the dose properly, they may experience symptoms of overdose such as decreased thirst and urination, headache, nausea, vomiting and muscle spasms, due to water retention and low sodium levels in the blood.

4 Healthcare institutions affected by the recall of the product have been informed by Ferring Pharmaceuticals Pte Ltd, and healthcare professionals have been advised to contact patients who had been prescribed the affected batches of medicine, for a review of their treatment options.

5 Patients are advised to check the batch number on their product. Those who are using the affected batches of Minirin Nasal Spray are advised to:

- a. Contact the healthcare provider from whom they have obtained their medicine to discuss alternative treatment options for their medical conditions. Inform their doctor if they are experiencing any side effects from taking the medicine.
- b. Do not stop using the medicine without discussing with their doctor as stopping treatment for CDI can result in increased urination, which can lead to dehydration and high sodium levels in the blood. Patients who are concerned about their current treatment can speak to their doctor or pharmacist.

6 For further enquiries, members of the public can contact Ferring Pharmaceuticals Pte Ltd at their hotline: 6812 7526.

**HEALTH SCIENCES AUTHORITY  
SINGAPORE  
24 JULY 2020**

---

▪ **About the Health Sciences Authority (HSA)**

The Health Sciences Authority (HSA) applies medical, pharmaceutical and scientific expertise through its three professional groups, Health Products Regulation, Blood Services and Applied Sciences, to protect and advance national health and safety. HSA is a multidisciplinary authority. It serves as the national regulator for health products, ensuring they are wisely regulated to meet standards of safety, quality and efficacy. As the national blood service, it is responsible for providing a safe and adequate blood supply. It also applies specialised scientific, forensic, investigative

and analytical capabilities in serving the administration of justice. For more details, visit <http://www.hsa.gov.sg/>.

For more updates on public health and safety matters, follow us on Twitter at [www.twitter.com/HSAsg](http://www.twitter.com/HSAsg).

▪ **About HSA Updates**

The “HSA Updates” seeks to provide current information, in a consistent and accurate manner, on topics of public interest. For all issues of HSA Updates, please visit [www.hsa.gov.sg](http://www.hsa.gov.sg) click “News & Events”, and select “HSA Updates”.

**Media representatives are welcome to send any queries to the Corporate Communications Department @ HSA.**

**Annex A**

Image showing the batch number of the bottle of Minirin Nasal Spray 10mcg/dose

